Satellos Bioscience (MSLE) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed NovaBridge Biosciences (NBP) over the past year, gaining 5.4% versus a loss of 68.6%. Over five years, MSLE leads with a -48.9% price change compared with -97.9% for NBP. Satellos Bioscience is the larger company by market cap ($161.9 million vs $158.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | NBP |
|---|---|---|
| Share price | $7.63 | $1.37 |
| Market cap | $161.88M | $158.92M |
| 1-day change | +1.19% | -2.14% |
| YTD return | +29.76% | -65.58% |
| 1-year return | +5.44% | -68.65% |
| 5-year return | -48.93% | -97.92% |
| EPS (TTM) | $-1.94 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.40 | $6.79 |
| 52-week low | $5.30 | $1.31 |
| Distance from 52-week high | -43.04% | -79.82% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +244.04% | +556.93% |
| Average volume | 51.35K | 387.52K |
| Shares outstanding | 21.22M | 116.00M |
| Employees | 18 | 30 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed NBP by 74.1 percentage points over the past year.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Healthcare · Biotechnology · 18 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
MSLE vs NBP FAQ
Which is bigger, Satellos Bioscience or NovaBridge Biosciences?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $161.88M compared with $158.92M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, MSLE or NBP?
MSLE returned +5.44% over the past 12 months, compared with -68.65% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are Satellos Bioscience and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.